Vessel-Sparing Radiation Successfully Treats Prostate Cancer, Maintains Quality of Life

Radiation therapy delivered to the critical vessels surrounding the prostate can result in erectile dysfunction and bladder and renal irritation. Vessel-sparing radiation and an improved understanding of the anatomy of the prostate can reduce these effects.

New Research Questions Recommendations Regarding PSA Tests for Prostate Cancer Screening

New Research Questions Recommendations Regarding PSA Tests for Prostate Cancer Screening

New research results favor testing for prostate specific antigen (PSA) levels for detection of prostate cancer. PSA tests can reduce the number of fatal cases of prostate cancer by detecting disease early.

Genetic Biomarker Predictive of Peripheral Neuropathy in Patients Receiving Docetaxel for Prostate Cancer

Docetaxel-induced neuropathy may be predicted by single nucleotide polymorphisms in VAC14.

Radiotherapy Plus Hormone Therapy Improves Long-term Survival for Patients With Prostate Cancer

Radiotherapy in combination with anti-androgen hormone therapy halves the risk of death from prostate cancer 15 years after diagnosis compared with hormone therapy alone.

Hsp90 Inhibition Overcomes Hormone Resistance in Some Aggressive Prostate Cancers

The second-generation hsp90 inhibitor onalespib may be beneficial for men with prostate cancer that no longer responds to androgen deprivation therapy

Diet Can Affect Aggressiveness of Prostate Cancer

Diet Can Affect Aggressiveness of Prostate Cancer

Research also suggests that statins may help counteract harmful effect of fatty foods

Physical Activity May Improve Prostate Cancer Prognosis

Physical Activity May Improve Prostate Cancer Prognosis

A moderate to high level of physical activity before and after diagnosis may improve prognosis in patients with non-metastatic prostate cancer.

Shortened Radiation Therapy Schedule No Worse Than Conventional Radiotherapy in Low-Risk Prostate Cancer

Shortened Radiation Therapy Schedule No Worse Than Conventional Radiotherapy in Low-Risk Prostate Cancer

Treatment with a hypofractionated radiotherapy (HRT) schedule achieved similar efficacy as treatment with the longer, conventional RT (CRT) schedule in men with low-risk prostate cancer.

Urine Test Accurately Identifies Tumor Grade in Prostate Cancer

Urine Test Accurately Identifies Tumor Grade in Prostate Cancer

A new urine assay that can detect genetic changes correlated with prostate cancer correctly identified cancer grade in 92% of men with elevated PSA levels and high-grade cancers.

AACR: Regular Pre-Diagnosis Exercise Ups Prostate Cancer Survival

AACR: Regular Pre-Diagnosis Exercise Ups Prostate Cancer Survival

Researchers found that men with prostate cancer who had exercised regularly had the best outcomes.

Higher Radiation Doses May Not Improve Survival in Localized Prostate Cancer

New technology has enabled doctors to administer higher doses of radiation to prostate cancer tumors with fewer side effects; however, escalating the dose of radiation may not help patients with localized prostate cancer in the long term.

The Relationship Between Location of Metastases and Overall Survival in Men with mCRPC

The Relationship Between Location of Metastases and Overall Survival in Men with mCRPC

Site of metastasis is key to the length of time a patient can survive metastatic castration-resistant prostate cancer (mCRPC).

Noncancer-related Hospitalizations Increase After Prostate Cancer Diagnoses in Elderly Men

Noncancer-related Hospitalizations Increase After Prostate Cancer Diagnoses in Elderly Men

Men age 67 years or older with prostate cancer were 37% more likely to be hospitalized for noncancer reasons after their cancer diagnosis than before their diagnosis.

GI/GU Toxicity, Radiation Exposure Lower With IMRT vs 3DCRT for Prostate Cancer

GI/GU Toxicity, Radiation Exposure Lower With IMRT vs 3DCRT for Prostate Cancer

Radiation doses to the bladder and rectum were reduced with intensity-modulated radiotherapy (IMRT) for prostate cancer.

Higher Treatment Volumes at Radiation Facilities Lead to Improved Overall Survival in Prostate Cancer

Higher Treatment Volumes at Radiation Facilities Lead to Improved Overall Survival in Prostate Cancer

Among men with aggressive prostate cancer, overall survival (OS) rates improve when they receive radiation treatment at facilities that frequently perform the treatment.

Bicalutamide Plus Everolimus May Be Effective for CRPC

Bicalutamide Plus Everolimus May Be Effective for CRPC

The combination of bicalutamide and everolimus may be effective in men with bicalutamide-naïve castration-resistant prostate cancer (CRPC).

Surgery Improves Survival After Radiotherapy Failure in Men With Prostate Cancer

A complex surgical procedure to remove the prostate achieves excellent long-term survival for men with prostate cancer after radiation therapy has failed.

Risk for Some Secondary Cancers After Radiotherapy For Prostate Cancer is Increased

Although reported absolute rates of second malignancies after radiotherapy for prostate cancer are very low, it is associated with higher rates of bladder, colon, and rectal cancers in patients who undergo radiotherapy for prostate cancer.

Serum Vitamin D Levels Predict Adverse Pathology at Prostatectomy

Both insufficiency and deficiency of serum vitamin D correlated with an increased risk of unfavorable pathology in men undergoing radical prostatectomy for prostate cancer.

Opting for Active Surveillance Increasing Among Men With Low-grade Prostate Cancer

Patients with slow-growing prostate cancer are increasingly opting for active surveillance and only changing treatment plan if the disease changes to a higher risk form to avoid unnecessary and potentially toxic treatments.

Short Androgen Suppression With RT Improves DFS in Localized Prostate Cancer

Short Androgen Suppression With RT Improves DFS in Localized Prostate Cancer

Adding 6 months of adjuvant androgen suppression to radiotherapy improves biochemical and clinical disease-free survival (DFS).

Use of Proton Therapy for Prostate Cancer Has Doubled

Use of Proton Therapy for Prostate Cancer Has Doubled

The use of proton therapy to treat patients with prostate cancer increased more than 2-fold from 2004 to 2012.

Overall Survival in mCRPC Worse for Men With Lung, Liver Metastases

Overall Survival in mCRPC Worse for Men With Lung, Liver Metastases

Overall survival (OS) is worse for men with castration-resistant prostate cancer (CRPC) metastases to the lung and liver.

Few Older Men Receiving Recommended Intensity of Active Surveillance

Few Older Men Receiving Recommended Intensity of Active Surveillance

Very few older man receive the intensity of active surveillance testing recommended by major prospective active surveillance (AS) programs.

Diagnostic Tool Can Smell Bladder Cancer or Prostate Cancer in a Urine Sample

Diagnostic Tool Can Smell Bladder Cancer or Prostate Cancer in a Urine Sample

Recent developments in a gas chromatography tool might allow doctors to determine whether urologic cancers are present via a urine sample.

Colorectal Cancer Risk Higher for Patients With a Prostate Cancer Diagnosis

Colorectal Cancer Risk Higher for Patients With a Prostate Cancer Diagnosis

The risk for developing colorectal cancer is increased after a diagnosis of prostate cancer.

Data Analyses Reveal Radium-223 Improves Quality of Life Measures for CRPC

Data Analyses Reveal Radium-223 Improves Quality of Life Measures for CRPC

Radium-223 dichloride (radium-223) improves overall survival in patients with castration-resistant prostate cancer (CRPC).

Heart Disease Is Most Common Cause of Death for Prostate Cancer Survivors

Survivors of prostate cancer should be made aware of an increased risk for heart disease. It is the most common noncancer cause of death for men with prostate cancer.

Novel Therapeutic Demonstrates Effectiveness Against Castration-resistant Prostate Cancer

The growth of castration-resistant prostate cancer cells was reduced by a first-in-class sphingosine kinase 2 inhibitor, but the cells were not killed.

Skeletal-related Events Linked With Worse Survival, Increased Costs

Men with prostate cancer and bone metastases that have experienced at least one skeletal-related event (SRE) show worse survival, according to a recent study.

PET Imaging Promising for Metastatic Prostate Cancer

PET Imaging Promising for Metastatic Prostate Cancer

Positron emission tomography (PET) imaging may offer a superior method of imaging for metastatic prostate cancer.

Prostate-Specific Antigen (PSA) Test (Fact Sheet)

Prostate-Specific Antigen (PSA) Test (Fact Sheet)

This fact sheet reviews the PSA test for prostate cancer, in particular screening recommendations, test limitations, and possible improvements the future may hold in store for the test.

Rates of Nonrecommended Screenings for Prostate and Breast Cancers Is High Among Older Patients

Among persons 65 years or older with limited life expectancies of less than 10 years, an estimated 15.7% may have undergone nonrecommended screenings for prostate and breast cancers.

CRPC: Enzalutamide Better Than Bicalutamide for Improving PFS

CRPC: Enzalutamide Better Than Bicalutamide for Improving PFS

Enzalutamide significantly reduced the risk of prostate cancer progression or death in prostate cancer.

Some Improvements in Survival, Skeletal Events Seen in Clinical Trial of Docetaxel Combo

Some Improvements in Survival, Skeletal Events Seen in Clinical Trial of Docetaxel Combo

Phase 3 results of the TRAPEZE trial of patients with bony metastatic castrate-refractory prostate cancer (CRPC).

Lethal Prostate Cancer Risk Lower With Regular Aspirin Use

Lethal Prostate Cancer Risk Lower With Regular Aspirin Use

The risk of lethal prostate cancer, but not of overall, high-grade, or advanced cancers, was reduced with regular aspirin use.

Novel Diagnostic Test Uses CTCs in Blood to Guide Treatment Decisions for Patients With Prostate Cancer

An experimental liquid biopsy using a blood sample may determine which patients with prostate cancer will benefit from hormone therapies.

Prostate Cancer Screening and Treatment Information Inadequate for Most Men

Prostate Cancer Screening and Treatment Information Inadequate for Most Men

Important discussions about prostate cancer screening and treatment are not occurring between men and their health care team.

In mCRPC, Docetaxel Active After Antiandrogen Therapy

A total of 40% of patients with mCRPC treated with docetaxel after abiraterone achieved at least a 50% reduction in PSA, according to a study presented at the 2016 Genitourinary Cancers Symposium.

Active Surveillance Criteria for Early Prostate Cancer May Not Be Accurate in African American Men

Active Surveillance Criteria for Early Prostate Cancer May Not Be Accurate in African American Men

African American men with Gleason score 3+3=6 prostate cancer produce less PSA and have significantly lower PSA density than white men, according to a new study. These findings could have important implications for treatment decision-making.

Risks of Adverse Effects Lower With Surgical Castration Vs. Chemical Castration for Metastatic Prostate Cancer

Surgical castration via orchiectomy for metastatic prostate cancer is associated with lower risks for adverse effects compared with medical castration via GnRHa therapy.

Familial Risk and Heritability of Cancer Is Higher Among Twins

Twins carry a significant excess familial risk for cancer overall and for specific types of cancer, including prostate, melanoma, breast, ovary, and uterus, according to a long-term follow-up study of twins in Nordic countries.

GnRH Agonists Associated With Higher Adverse Effect Risk vs Orchiectomy

Gonadotropin-releasing hormone agonist (GnRHa) therapy is associated with increased risks of numerous clinically relevant adverse events compared with orchiectomy.

Intermittent ADT for Prostate Cancer Does Not Reduce Long-term Effects

A study compared the number of adverse events caused by both intermittent and continuous androgen-deprivation therapy (ADT) for prostate cancer.

Patients' Expectations After Radical Prostatectomy May Be Unrealistic

Patients with prostate cancer who have undergone radical prostatectomy have largely unrealistic expectations with respect to their postoperative sexual function.

Docetaxel With Long-term Hormone Therapy Improves Survival in Prostate Cancer

Docetaxel should be added at initiation of standard of care treatment in men with prostate cancer; however, no evidence of survival improvement was seen with zoledronic acid therefore it is not recommended as part of standard of care for this patient population.

Tumor Location and Duration of Therapy Influence Palliative Effects of Radiation Therapy for Painful Bone Metastases

Tumor Location and Duration of Therapy Influence Palliative Effects of Radiation Therapy for Painful Bone Metastases

In a review of the Dutch Bone Metastasis Study results, stratified for primary tumor location, palliative radiation therapy was found to reduce pain and improve quality of life for some patients.

Repeating PSA Test in Select Patients Can Mitigate Controversial Issues in Prostate Cancer Screening

Repeating PSA Test in Select Patients Can Mitigate Controversial Issues in Prostate Cancer Screening

Some task forces advocate abandoning the use of the screening PSA test because it leads to unnecessary prostate biopsies. Canadian researchers show that repeating the test in select patients can reduce the number of biopsies.

Age and Cancer Site Influence Excess Financial Burden of Cancer Survivorship

Economic burden is significantly higher for survivors of colorectal, breast, and prostate cancers compared with persons with no cancer history; however, excess economic burden attributable to cancer varies by cancer site and age.

Medical Records Reveal Alzheimer Diagnoses Higher Among Patients Receiving ADT for Prostate Cancer

In a study that demonstrates the emerging technique of extracting biomedical data from ordinary patient medical records, a nearly 2-fold increase was seen in the rate of Alzheimer disease diagnoses among men with prostate cancer who received ADT.

Soccer Strengthens Bones of Men With Prostate Cancer

Men with prostate cancer are at risk for brittle bones as an adverse effect of their treatment; however, 1 hour of soccer training a few times a week counters many of the negative effects of treatment.

Novel Imaging Agent More Effectively Monitors Impact of Treatment in Lung, Prostate Cancers

Novel Imaging Agent More Effectively Monitors Impact of Treatment in Lung, Prostate Cancers

A method to better trace changes in cancers and treatment of the prostate and lung without the limitations associated with radiation has been developed.

Vigorous Exercise and Other Healthy Lifestyle Habits May Protect Against Lethal Prostate Cancer

Vigorous Exercise and Other Healthy Lifestyle Habits May Protect Against Lethal Prostate Cancer

A study that tracked tens of thousands of midlife and older men for more than 20 years has found that vigorous exercise and other healthy lifestyle habits may reduce their chances of developing a lethal type of prostate cancer by up to 68%.

Patients With Prostate Cancer Receiving Active Surveillance May Not Be Properly Monitored

Patients With Prostate Cancer Receiving Active Surveillance May Not Be Properly Monitored

Men undergoing active surveillance for low-risk prostate cancer may not be receiving proper monitoring.

Rates of PSA Screening and Early Stage Prostate Cancer Are Declining

Rates of PSA Screening and Early Stage Prostate Cancer Are Declining

The impact on PSA screening and prostate cancer incidence before and after the 2012 USPSTF screening recommendations were examined in two recent studies.

Yoga May Increase Quality of Life for Prostate Cancer Patients

Yoga May Increase Quality of Life for Prostate Cancer Patients

A small study shows those undergoing radiation therapy had fewer side effects and less fatigue when practicing yoga.

New Blood Test Improves Screening for Prostate Cancer

New Blood Test Improves Screening for Prostate Cancer

A new test is better at detecting aggressive prostate cancer than measuring PSA levels. The new test discovers aggressive cancer earlier and reduces the number of false positive tests and unnecessary biopsies.

Blood Test Identifies Mutations Behind Drug Resistance in Patients Taking Antiandrogen for Prostate Cancer

Scientists developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug and which patients will not respond to the treatment in advance.

Yoga May Reduce Side Effects in Patients Receiving Treatment for Prostate Cancer

Yoga May Reduce Side Effects in Patients Receiving Treatment for Prostate Cancer

Patients who are undergoing radiotherapy for prostate cancer may benefit from yoga.

PSA Screening Rates Have Declined Since 2012 USPSTF Recommendation Update

PSA Screening Rates Have Declined Since 2012 USPSTF Recommendation Update

Both the incidence of early stage prostate cancer and rates of prostate-specific antigen (PSA) screening oincide with the 2012 USPSTF recommendation.

ADT Associated With Self-reported Physical Functioning, Muscle Strength Decline

ADT Associated With Self-reported Physical Functioning, Muscle Strength Decline

Androgen deprivation therapy is associated with declines in self-reported physical functioning and upper body muscle strength.

Study Reveals Wide Variation in Costs of Radiation Treatments for Low-Risk Prostate Cancer

Study Reveals Wide Variation in Costs of Radiation Treatments for Low-Risk Prostate Cancer

The cost of treatment for low-risk prostate cancer varies widely. A new study examined the cost of care from when a patient checks in for his first appointment through his posttreatment follow-up testing via the use of time-driven activity-based costing.

Patient Age, Tumor Risk Associated with Expectant Management Use for Veterans With Prostate Cancer

Patient Age, Tumor Risk Associated with Expectant Management Use for Veterans With Prostate Cancer

For veterans with early-stage prostate cancer, patient age and tumor risk were found to be more strongly associated with use of expectant management.

Racial Differences in Outcomes and Costs of Care in Older Men with Prostate Cancer

Racial Differences in Outcomes and Costs of Care in Older Men with Prostate Cancer

Older black men with localized prostate cancer were more likely to have poorer quality care, incur higher costs, and have worse postoperative outcomes than white men. However, that did not translate to worse overall or cancer-specific survival.

Antiandrogen Therapy (AAT) Improves Survival In Prostate Cancer Recurrence After Prostatectomy

Antiandrogen Therapy (AAT) Improves Survival In Prostate Cancer Recurrence After Prostatectomy

Overall survival in men with rising PSA levels after prostatectomy for prostate cancer was statistically improved by adding a 24-month course of AAT during and after salvage radiotherapy, compared with salvage radiotherapy alone.

Shortened Radiotherapy Schedule Has Similar Benefit as Longer Schedule for Low-Risk Prostate Cancer

Clinical trial results confirm that newly diagnosed early stage prostate cancer can be treated with hypofractionated radiotherapy and experience the same level of cancer control as those treated with conventional radiotherapy.

Metastatic Prostate Cancer With DNA-Repair Defects Responded to Treatment With Olaparib

Metastatic Prostate Cancer With DNA-Repair Defects Responded to Treatment With Olaparib

A high response rate was seen among patients whose metastatic castration-resistant prostate cancers had DNA-repair defects.

Prostate Tumors Reprogram, Instead of Rewrite, DNA Code to Form Tumors

Scientists have gained a key insight into how prostate tumors get their start. Instead of rewriting the normal DNA code, the master regulator of genes in prostate cells is reprogrammed to drive malignant growth.

Black Patients With Prostate Cancer Treated With Surgery More Likely to Experience Adverse Events

Black Patients With Prostate Cancer Treated With Surgery More Likely to Experience Adverse Events

Black patients treated with radical prostatectomy for localized prostate cancer (PCa) are more likely to experience adverse events.

ASTRO: Men's Health Supplements Not Helpful for Prostate Cancer

ASTRO: Men's Health Supplements Not Helpful for Prostate Cancer

No reduction in risk of distant metastasis, cancer-related deaths, radiation-linked adverse effects were connected to the use of men's health supplements (MHSs).

Testosterone Therapy Does Not Increase Aggressive Prostate Cancer Risk

Testosterone Therapy Does Not Increase Aggressive Prostate Cancer Risk

Use of testosterone therapy has increased in the last decade and the potential long-term risks associated with this therapy have been of concern.

Newly Identified Gene Mutations May Expand Indications for Existing Targeted Cancer Treatments

Newly Identified Gene Mutations May Expand Indications for Existing Targeted Cancer Treatments

Researchers identified two new cancer-causing gene mutations that could lead to more targeted and effective treatments for certain lung and prostate cancers.

Molecular Imaging Study Reveals Improved Detection of Early Stage Recurrent Prostate Cancer

Molecular Imaging Study Reveals Improved Detection of Early Stage Recurrent Prostate Cancer

In the study, management was changed in 44% more cases by Use of the imaging agent Ga-68 PSMA with PET/CT resulted in a change in management of prostate cancer in 44% more cases than with another widely used agent.

Androgen deprivation therapy associated with increased risk for fatal heart attack

Androgen deprivation therapy associated with increased risk for fatal heart attack

Evidence suggests that androgen deprivation therapy is associated with nonfatal cardiovascular events.

More men at risk for prostate cancer as a result of less regular screening

More men at risk for prostate cancer as a result of less regular screening

A recent study examined the potential benefits and potential downsides to the USPSTF recommendation against regular PSA screening.

Electronic trigger reduces delays in evaluation for cancer diagnosis

Electronic triggers designed to search for key data were able to identify and reduce follow-up delays for patients being evaluated for a diagnosis of colon or prostate cancer.

PET imaging detects fast-growing prostate cancer

PET imaging detects fast-growing prostate cancer

A molecular imaging biomarker is able to detect fast-growing primary prostate cancer.

Mushroom powder may have potential for prostate cancer treatment

Mushroom powder may have potential for prostate cancer treatment

Treatment with mushroom powder led to reduction in prostate-specific antigen level in some patients with biochemical recurrence.

Two-drug combination boosts survival in patients with metastatic prostate cancer

A combination therapy increased survival rates for individuals with newly diagnosed metastatic, hormone-sensitive prostate cancer.

Tell me about your prostate cancer symptoms ... Will most men talk or walk?

Tell me about your prostate cancer symptoms ... Will most men talk or walk?

Approximately 97% of men with advanced prostate cancer report being comfortable discussing their symptoms with their health care team. But the number of men who actually do so is significantly lower.

Long-term denosumab therapy safe for patients with breast, prostate cancer

Long-term denosumab therapy safe for patients with breast, prostate cancer

No new safety signals were identified for long-term denosumab therapy in patients with metastatic breast or prostate cancer and bone metastases.

ADT impacts mood of patients with prostate cancer, as perceived by partners

ADT impacts mood of patients with prostate cancer, as perceived by partners

Androgen deprivation therapy negative impacts the mood of patients with prostate cancer.

Prostate cancer not likely to be cause of death in men with low-risk disease

Prostate cancer not likely to be cause of death in men with low-risk disease

Relatively unaggressive prostate tumors are not likely to develop into metastatic disease or result in death.

New biomarker in breast and prostate cancer may help identify patients who will respond to taxanes

New biomarker in breast and prostate cancer may help identify patients who will respond to taxanes

Researchers have pinpointed a novel genetic biomarker responsible for the progression of many breast and prostate cancers.

Risk of cancer in the prostate gland may be caused by exposure to bisphenol A (BPA) during organ development

A prostate organoid grown from human embryonic stem cells has enabled researchers to show that exposure to bisphenol A (BPA) may increase prostate cancer risk.

Molecular tinkering doubles cancer drug's efficacy

By surrounding molecules of paclitaxel with self-assembling spheres composed of amino acids, researchers doubled tumor exposure to the drug and reduced its effects on healthy tissue.

Prostate cancer treatment is trending toward risk-specific therapies

Patients receiving treatment for prostate cancer are now more likely to receive medical care matched to their level of risk.

Radiotherapy costs vary among Medicare patients with breast, lung, prostate cancers

Radiotherapy costs vary among Medicare patients with breast, lung, prostate cancers

Cost of radiotherapy among Medicare patients varied most widely because of year of diagnosis, location of treatment, clinic type, and provider.

Study findings do not support association between prostate cancer incidence and shift work

Shift workers do not develop prostate cancer more frequently than their day-shift colleagues, research indicates.

Genomic fingerprint may predict aggressive prostate cancer in African Americans

Genomic fingerprint may predict aggressive prostate cancer in African Americans

African American men are more likely to develop prostate cancer than European American men, and are also more than twice as likely to die from it.

Comparison of zoledronic acid dosing schedules finds less frequent schedule noninferior

Comparison of zoledronic acid dosing schedules finds less frequent schedule noninferior

ASCO 2015: 12-week dosing schedule of zoledronic acid is noninferior to a more-frequent schedule of every 4 weeks.

Researchers identify lynchpin molecule for prostate cancer metastasis

Researchers identify lynchpin molecule for prostate cancer metastasis

A single molecule appears to be the central regulator driving metastasis in prostate cancer.

Black men twice as likely to die from prostate cancer compared to white men

Black men twice as likely to die from prostate cancer compared to white men

Black men are twice as likely to be diagnosed with, or die from, prostate cancer in their lifetime compared to white men.

Research findings differentiate prostate cancer tumors into five different types

Research findings differentiate prostate cancer tumors into five different types

Prostate cancer has five distinct types, with different ways to determine which type of tumor a patient has.

Sensor technology can improve accuracy of prostate cancer diagnosis

Sensor technology can improve accuracy of prostate cancer diagnosis

A sensor chip, able to pick up on differences in glycoprotein molecules, can improve accuracy and efficiency of prostate cancer diagnosis.

More patients with prostate cancer being treated appropriately based on risk

More patients with prostate cancer being treated appropriately based on risk

Patients with prostate cancer are now more likely to receive medical care matched to risk level.

Low-risk prostate cancer cases often upgraded at prostatectomy

Low-risk prostate cancer cases often upgraded at prostatectomy

A recent study indicates a high rate of clinical upgrading at prostatectomy, based on over ten thousand patients reviewed.

Dose-escalated radiation does not benefit patients with low-risk prostate cancer

Dose-escalated radiation does not benefit patients with low-risk prostate cancer

Higher radiation dose is associated with improved survival rates among men with medium- and high-risk prostate cancer.

Surveillance being utilized more for prostate cancer

Surveillance being utilized more for prostate cancer

Many men with low-risk disease being spared prostatectomy, radiation, and androgen deprivation monotherapy in favor of active surveillance.

Expectant management of very low-, low-risk prostate cancer is effective, but underused

Expectant management of very low-, low-risk prostate cancer is effective, but underused

Using watchful waiting or active surveillance to monitor men with very low- and low-risk prostate cancer is effective in many patients with localized tumors and could prevent aggressive and unnecessary treatments.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs